ZA202110111B - Methods and compositions for treating liver disorders - Google Patents
Methods and compositions for treating liver disordersInfo
- Publication number
- ZA202110111B ZA202110111B ZA2021/10111A ZA202110111A ZA202110111B ZA 202110111 B ZA202110111 B ZA 202110111B ZA 2021/10111 A ZA2021/10111 A ZA 2021/10111A ZA 202110111 A ZA202110111 A ZA 202110111A ZA 202110111 B ZA202110111 B ZA 202110111B
- Authority
- ZA
- South Africa
- Prior art keywords
- compositions
- methods
- liver disorders
- disorders
- treating liver
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 208000019423 liver disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000024891 symptom Diseases 0.000 abstract 2
- 230000003871 intestinal function Effects 0.000 abstract 1
- 230000000813 microbial effect Effects 0.000 abstract 1
- 230000000116 mitigating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Zoology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962850773P | 2019-05-21 | 2019-05-21 | |
| PCT/US2020/033870 WO2020236979A1 (en) | 2019-05-21 | 2020-05-20 | Methods and compositions for treating liver disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202110111B true ZA202110111B (en) | 2024-04-24 |
Family
ID=73458208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2021/10111A ZA202110111B (en) | 2019-05-21 | 2021-12-07 | Methods and compositions for treating liver disorders |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220211780A1 (https=) |
| EP (1) | EP3973047A4 (https=) |
| JP (1) | JP2022533672A (https=) |
| KR (1) | KR20220011683A (https=) |
| CN (1) | CN113993529A (https=) |
| AU (1) | AU2020278703A1 (https=) |
| CA (1) | CA3140096A1 (https=) |
| SG (1) | SG11202112515RA (https=) |
| WO (1) | WO2020236979A1 (https=) |
| ZA (1) | ZA202110111B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201903823QA (en) | 2014-10-31 | 2019-05-30 | Whole Biome Inc | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| CN111372596A (zh) | 2017-08-30 | 2020-07-03 | 潘德勒姆治疗公司 | 用于治疗微生物组相关病症的方法和组合物 |
| CA3106315A1 (en) | 2018-07-19 | 2020-01-23 | Pendulum Therapeutics, Inc. | Methods and compositions for microbial engraftment |
| SG11202112515RA (en) * | 2019-05-21 | 2021-12-30 | Pendulum Therapeutics Inc | Methods and compositions for treating liver disorders |
| NL2030011B1 (en) * | 2021-12-03 | 2023-06-20 | Caelus Pharmaceuticals B V | Prevention or treatment of hepatic steatosis |
| EP4467148A4 (en) * | 2022-01-20 | 2025-04-23 | Korea Institute of Science and Technology | Composition for prevention, amelioration or treatment of non-alcoholic fatty liver disease, comprising extracellular vesicles derived from roseburia spp. or bifidobacterium spp |
| CN117599092B (zh) * | 2024-01-23 | 2024-04-26 | 南方医科大学南方医院 | 生孢梭菌在制备预防和/或治疗肝脏疾病的药物中的应用 |
| CN118526527A (zh) * | 2024-03-19 | 2024-08-23 | 华中科技大学同济医学院附属协和医院 | 益生菌混合液在制备预防或治疗apap诱导肝损伤药物中的应用 |
| KR102679094B1 (ko) * | 2024-04-24 | 2024-06-27 | 충남대학교 산학협력단 | 항비만 효능을 지닌 한국인 마이크로바이옴 유래 클로스트리디움 부티리쿰 균주 및 이의 용도 |
| CN119639633A (zh) * | 2025-02-18 | 2025-03-18 | 杭州师范大学附属医院(杭州市第二人民医院) | 一种治疗非酒精性脂肪肝的酵母菌益生菌复合物及其制备方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201903823QA (en) * | 2014-10-31 | 2019-05-30 | Whole Biome Inc | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| EP3402475B1 (en) * | 2016-01-11 | 2021-10-20 | Egetis Therapeutics AB | Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions |
| AU2017370681A1 (en) * | 2016-12-06 | 2019-06-27 | Pendulum Therapeutics, Inc. | Methods and compositions relating to isolated and purified microbes |
| CN111372596A (zh) * | 2017-08-30 | 2020-07-03 | 潘德勒姆治疗公司 | 用于治疗微生物组相关病症的方法和组合物 |
| AU2018341734B2 (en) * | 2017-09-28 | 2022-02-03 | Kobiolabs, Inc. | Composition for diagnosis and treatment of alcoholic liver disease, using change in short-chain fatty acid producing gut bacterial community |
| CA3113684A1 (en) * | 2018-09-24 | 2020-04-02 | Pendulum Therapeutics, Inc. | Microbial compositions and methods of use |
| SG11202112515RA (en) * | 2019-05-21 | 2021-12-30 | Pendulum Therapeutics Inc | Methods and compositions for treating liver disorders |
-
2020
- 2020-05-20 SG SG11202112515RA patent/SG11202112515RA/en unknown
- 2020-05-20 WO PCT/US2020/033870 patent/WO2020236979A1/en not_active Ceased
- 2020-05-20 CN CN202080043100.6A patent/CN113993529A/zh active Pending
- 2020-05-20 KR KR1020217041642A patent/KR20220011683A/ko not_active Withdrawn
- 2020-05-20 JP JP2021568854A patent/JP2022533672A/ja active Pending
- 2020-05-20 AU AU2020278703A patent/AU2020278703A1/en not_active Abandoned
- 2020-05-20 EP EP20809882.2A patent/EP3973047A4/en not_active Withdrawn
- 2020-05-20 US US17/610,398 patent/US20220211780A1/en not_active Abandoned
- 2020-05-20 CA CA3140096A patent/CA3140096A1/en active Pending
-
2021
- 2021-12-07 ZA ZA2021/10111A patent/ZA202110111B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3140096A1 (en) | 2020-11-26 |
| EP3973047A1 (en) | 2022-03-30 |
| EP3973047A4 (en) | 2023-01-11 |
| US20220211780A1 (en) | 2022-07-07 |
| CN113993529A (zh) | 2022-01-28 |
| KR20220011683A (ko) | 2022-01-28 |
| SG11202112515RA (en) | 2021-12-30 |
| WO2020236979A1 (en) | 2020-11-26 |
| JP2022533672A (ja) | 2022-07-25 |
| AU2020278703A1 (en) | 2022-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202110111B (en) | Methods and compositions for treating liver disorders | |
| ZA202204929B (en) | Rimegepant for cgrp related disorders | |
| PH12019500521A1 (en) | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer | |
| MY206230A (en) | Amyloid precursor protein (app) rnai agent compositions and methods of use thereof | |
| EP4140487A8 (en) | Combination therapy for treating cancer | |
| PH12021552763A1 (en) | Treatment and prevention of metabolic diseases | |
| WO2019032662A8 (en) | Clec9a binding agents and use thereof | |
| MX361467B (es) | Compuestos de isoindolina para uso en el tratamiento de cancer. | |
| EA201200793A1 (ru) | Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин | |
| EP3708168A3 (en) | Combinations of deuterated dextromethorphan and quinidine for the treatment of agitation in dementia | |
| NZ799031A (en) | Solid forms of berberine ursodeoxycholate and compositions and methods thereof | |
| WO2015095834A3 (en) | Cancer treatments using erk1/2 and bcl-2 family inhibitors | |
| BR112012022552A2 (pt) | uso de fenoterol e de anélogos de fenoterol no tratamento de gliobastomas e astrocitomas | |
| BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
| PH12020500666A1 (en) | Pladienolide compounds and their use | |
| MX2015009696A (es) | Composiciones estables que comprenden heparinoide, anestesico de accion aguda y regulador de ph. | |
| MX2021009247A (es) | Metodos, sistemas y kits para tratar enfermedades inflamatorias que se dirigen a il18r1. | |
| PH12019502086A1 (en) | Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | |
| PH12018501790A1 (en) | Treatment of patients with homozygous familial hypercholesterolemia on lipid lowering therapy | |
| WO2020039088A3 (en) | Aromatic molecules for use in the treatment of pathological conditions | |
| MX2017009963A (es) | Composición y método para el tratamiento de padecimientos de la piel. | |
| MX2020007619A (es) | Intervenciones dirigidas, encaminadas a reducir los niveles de succinato circulante en un sujeto, y kits y metodo para determinar la eficacia de dichas intervenciones. | |
| MX2023014484A (es) | Uso de roluperidona para tratar sintomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroproteccion. | |
| BR112022007010A2 (pt) | Terapia gênica para doença de alzheimer | |
| HK1219896A1 (zh) | 使用4-氨基-2-(2,6-二氧代-呱啶-3-基)-异吲哚啉-1,3-二酮治疗和控制中枢神经系统癌症的方法和组合物 |